Categories: Health

Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

 | Source: Anika Therapeutics Inc.

BEDFORD, Mass., June 05, 2025 (GLOBE NEWSWIRE) — Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the osteoarthritis pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that on June 2, 2025, Anika granted non-statutory stock options (“Options”) covering an aggregate of 2,500 shares of common stock at a per share exercise price of $11.45, which equaled the closing price of common stock on the Nasdaq Global Select Market (“Closing Price”) on the grant date, to one newly hired non-executive employee. The grant was made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, was approved by the compensation committee of the board of directors pursuant to a delegation of authority by the board of directors, and, in accordance with Nasdaq Listing Rule 5635(c)(4), was made as a material inducement to the grantee’s acceptance of employment with Anika as a component of the grantee’s employment compensation.

Of the shares covered by the Options, one-third will vest on each of the first three anniversaries of the grant date, in each case for so long as the grantee provides continuous service to Anika through the relevant vesting date.

Unless earlier terminated in accordance with their terms, the Options will expire on the tenth anniversary of the grant date and are otherwise subject to the terms and conditions of the equity award agreement approved by Anika. The Options were granted pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, which was not subject to stockholder approval.

About Anika

Anika Therapeutics, Inc. (NASDAQ: ANIK), is the global leader in the design, development, manufacturing, and commercialization of hyaluronic acid innovations. In partnership with clinicians, our sole focus is dedicated to delivering and advancing osteoarthritis pain management and orthopedic regenerative solutions. At our core is a passion to deliver a differentiated portfolio that improves patient outcomes around the world. Anika’s global operations are headquartered outside of Boston, Massachusetts. For more information about Anika, please visit www.anika.com.

For Investor Inquiries:
Anika Therapeutics, Inc.
Matt Hall, 781-457-9554
Director, Corporate Development and Investor Relations
investorrelations@anika.com

GlobeNews Wire

Recent Posts

2025 GENESIS SCOTTISH OPEN TEES UP ICONIC PLAYERS AND EXHILARATING FAN EXPERIENCES

The 2025 Genesis Scottish Open field features 156 top players, including eight of the top…

50 minutes ago

GENESIS MOTOR UK DEBUTS ENHANCED GV60

New Genesis GV60 now available to order in the UKPriced from £54,115 OTR in Pure…

50 minutes ago

Hyundai Motor and Kias Robotics LAB Delivers First Xble Shoulder Wearable Robot to Korean Air

Hyundai Motor and Kia launch Korean sales of the industrial wearable robot X-ble Shoulder, with…

50 minutes ago

KuCoin Completes Independent Hacken-Audited Proof of Reserves

Achieves the 32nd Consecutive Month of Publishing PoR Reports, Sustaining over 100% Coverage VICTORIA, Seychelles,…

3 hours ago

India, China & Japan rank amongst world’s top 10 tech markets in 2025: Colliers

6 Indian markets feature in the top 10 list for tech talent acquisition across the…

3 hours ago

BugleRock Capital’s Global AUA Surpasses $4 Billion USD

 Launches Fixed Income Advisory Services with Expert Team BENGALURU, India, July 8, 2025 /PRNewswire/ --…

3 hours ago